IntroductionThe tyrosine-kinase inhibitor osimertinib is an oral anti-cancer agent that is used for the treatment of patients with metastatic non-small cell lung cancer harbouring sensitising <i>EGFR</i> mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.